Clinical trials: Tp53 Mutations
P53 Mutation in Esophageal Cancer
ESCC Molecular Subtypes Based on Multidimensional Features of p53 and Their Clinical Significance
Collect 300 esophageal cancer tissue specimens, including cancer tissue and serum, from a biological sample bank. Collect clinical information on esophageal cancer, including gender, age, time of diagnosis, time of death…
- Trial name
- NCT07722819
- Testing
- No intervention
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Ling Zhiqiang
Diffuse Large B-Cell Lymphoma
First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP
Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma。The majority of refractory patients have PD-L1 expression due to P53 mutations, some of which account for about 10% of DLBCL.Our department has found that…
- Trial name
- NCT05280626
- Testing
- Sintilimab, Rituximab
- Volunteers
- 100 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Ovarian Cancer, Small Cell Lung Cancer
A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation
This is a first-in-human, Phase 1/2, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of LG00313112 in participants with advanced solid malignancies harboring a TP53 Y220C…
- Conditions
- Ovarian Cancer, Small Cell Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer
- Trial name
- NCT07752875
- Testing
- LG00313112
- Volunteers
- 250 people
- Sponsor
- LG Chem
Cancer, Skin Fibroblasts
Nicotinamide Riboside on Mitochondrial Function in Li-Fraumeni Syndrome
Background: Nicotinamide riboside (NR) is a vitamin B3 dietary supplement. It may help improve muscle function, that may in turn may improve a person s exercise capacity.
- Conditions
- Cancer, Skin Fibroblasts, Muscle Weakness
- Trial name
- NCT03789175
- Testing
- Nicotinamide Riboside (NR)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Uterine Cancer, Endometrial Cancer
Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
The purpose of this study is to determine the recommended Phase 2 dose of zanzalintinib when given in combination with paclitaxel in patients with recurrent high-grade uterine cancer.
- Trial name
- NCT06795009
- Testing
- Zanzalintinib, Paclitaxel
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Washington University School of Medicine
Diffuse Large B-Cell Lymphoma (DLBCL)
Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation
To evaluate the efficacy and safety of Genetic subtype-matched targeted therapy in the treatment of treatment-naive diffuse large B-cell lymphoma with TP53 mutation.
- Trial name
- NCT07499271
- Testing
- POLA-R-CHP, Orelabrutinib
- Where
- China
- Volunteers
- 35 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Endometrial Cancer
The Role of Hypoxia as a Selective Pressure for TP53 Mutations
The study aims to develop scans that tell the investigators about the oxygen content of tumours using Magnetic Resonance Imaging (MRI) and seeing whether regions of low oxygen content are related to mutations in cancer genes such…
- Trial name
- NCT03466034
- Where
- United Kingdom
- Volunteers
- 5 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant malignancies
- Conditions
- Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT05877599
- Testing
- NT-175
- Where
- 20 sites in United States
- Volunteers
- 45 people
- Sponsor
- AstraZeneca
Relapsed/Refractory Acute Myeloid Leukemia
Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
The aim of PERKA-812-003 study is to investigate the safety, pharmacokinetics and preliminary anti-tumor activity of treatment with NMS-03597812 as single agent in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients who…
- Trial name
- NCT06549790
- Testing
- NMS-03597812
- Where
- 7 sites in United States
- Volunteers
- 124 people
- Sponsor
- Nerviano Medical Sciences
Colorectal Cancer Metastatic, Colorectal Cancer Stage IV
The p53 Colorectal Cancer Trial
Single center, open labeled, phase 2 clinical trial, where patients with metastatic colorectal cancer are selected for treatment with dose dense Cyclophosphamide every second week based on TP53 mutation status; i.e.
- Conditions
- Colorectal Cancer Metastatic, Colorectal Cancer Stage IV, TP53 Gene Mutation
- Trial name
- NCT03149679
- Testing
- Cyclophosphamide
- Where
- Norway
- Volunteers
- 12 people
- Sponsor
- Haukeland University Hospital
Mantle Cell Lymphoma Recurrent
Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma
This is an open label, multi-center, single-arm, phase II study investigating the efficacy and safety of the combination of ibrutinib and Tisagenlecleucel in twenty patients with relapsed or refractory Mantle Cell Lymphoma (MCL)…
- Trial name
- TARMAC (NCT04234061)
- Testing
- ibrutinib and Tisagenlecleucel
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Li-Fraumeni Syndrome, Neoplasms
Clinical and Genetic Studies of Li-Fraumeni Syndrome
Background: Li-Fraumeni syndrome (LFS) is a genetic condition that increases the risk for some types of cancer. LFS may lead to cancer of the bone or connective tissue, breast, and brain.
- Conditions
- Li-Fraumeni Syndrome, Neoplasms, Tp53 Mutations
- Trial name
- NCT01443468
- Where
- 2 sites in United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer
Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation
This is a prospective, single-arm, multicenter, phase II study to investigate the efficacy and safety of Ensartinib plus Bevacizumab in metastatic anaplastic lymphoma kinase (ALK)-rearranged Non-Small Cell Lung Cancer (NSCLC)…
- Trial name
- EAGLE (NCT05491811)
- Testing
- Ensartinib, Bevacizumab
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Sun Yat-sen University
Squamous Cell Carcinoma
A Biomarker-implemented Clinical Study Evaluating Mutations in MET and TP53 in a Population of Treatment-refractory Squamous Cell Carcinoma
Afatinib is approved therapy for SCC of the lung after progression with standard of care chemotherapy. There is also evidence of improvement of progression free survival of patients with metastatic/recurrent SCC of the head and…
- Trial name
- NCT04533321
- Testing
- Afatinib
- Where
- Singapore
- Volunteers
- 20 people
- Sponsor
- National University Hospital, Singapore
Chronic Lymphocytic Leukemia (CLL)
A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation
This study will evaluate the efficacy and safety of venetoclax and obinutuzumab (VEN + G) compared with fludarabine + cyclophosphamide + rituximab or bendamustine + rituximab (FCR/BR) in FIT participants (FIT is defined by a…
- Trial name
- CRISTALLO (NCT04285567)
- Testing
- Obinutuzumab, Venetoclax, Fludarabine
- Where
- 40 sites in United States, Australia and 3 more
- Volunteers
- 166 people
- Sponsor
- Hoffmann-La Roche
P53 Mutation, Myeloid Malignancy
Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS
TP53 mutation is commonly associated with poor cancer patient prognosis yet no mutant p53 (mp53)-targeting regimen was clinically established.
- Conditions
- P53 Mutation, Myeloid Malignancy, MDS, Aml
- Trial name
- PANDA-T0 (NCT03855371)
- Testing
- Decitabine, Arsenic Trioxide
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Ruijin Hospital
Refractory Solid Tumors
Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation
This study is an open, prospective, single arm, multi center exploratory basket clinical study. 20 refractory solid tumors patients with rescuable p53 mutation will be enrolled, and the efficacy and safety of arsenic trioxide in…
- Trial name
- NCT04869475
- Testing
- Arsenic trioxide
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ruijin Hospital
B-Cell Chronic Lymphocytic Leukemia, B-Lymphocytic Leukemia, Chronic
Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Background: Chronic lymphocytic leukemia and small lymphocytic lymphoma (hereby referred as CLL) are tumors of B cells. A subset of patients categorized as high-risk CLL has a poor clinical outcome when treated with conventional…
- Conditions
- B-Cell Chronic Lymphocytic Leukemia, B-Lymphocytic Leukemia, Chronic, Chronic Lymphocytic Leukemia, Leukemia, Chronic Lymphatic
- Trial name
- NCT03204188
- Testing
- Ibrutinib, Fludarabine, Pembrolizumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Endometrial Carcinoma, P53 Mutation
A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer
This is an umbrella, two-arm, multi-stage, phase II trial. The purpose of the trial in the early stage cohort is to determine if EBRT improves disease free survival (defined as the time from random assignment to disease…
- Conditions
- Endometrial Carcinoma, P53 Mutation, Serous Carcinoma
- Trial name
- CAN-STAMP (NCT04159155)
- Testing
- External Beam Radiation, Niraparib, Vaginal high-dose rate brachytherapy
- Where
- Canada
- Volunteers
- 11 people
- Sponsor
- University Health Network, Toronto
Breast Cancer
Duct Endoscopy in Assessing Cellular Atypia in the Breast Duct Fluid of Women With a Genetic Risk for Breast Cancer
RATIONALE: Diagnostic procedures, such as breast duct endoscopy, may improve the ability to detect breast cancer earlier and plan more effective treatment.
- Trial name
- NCT00082979
- Testing
- cytogenetic analysis, proteomic profiling, cytology specimen collection procedure
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- Royal Marsden NHS Foundation Trust